This termination has negligible financial impact given the $49,000 quarterly revenue contribution. Monitor Aytu's pipeline and next quarterly report for revenue composition changes, but this specific event does not warrant position adjustment.
Price Chart
Executive Summary
Aytu BioPharma and Lannett Company mutually terminated their exclusive license agreement for Metadate CD, effective June 23, 2026. The product generated only $49,000 in net revenue for the quarter ended March 31, 2026, making this termination a non-material event for a $24M market cap company.
Key Facts
- Exclusive license agreement (Metadate CD) terminated on June 23, 2026, by mutual agreement with Lannett Company
- Agreement originally signed May 11, 2022, amended in 2023 and 2025
- Aytu may continue selling existing inventory and paying royalties until sales cease
- Net revenue from Metadate CD was only $49,000 for the quarter ended March 31, 2026
Financial Impact
The terminated product generated only $49,000 in quarterly revenue — a trivial amount for a $24M market cap company. No material financial impact.
Risk Factors
- Loss of any future royalty stream from Metadate CD sales, though historically immaterial
- Potential strategic implications if this signals broader partnership deterioration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021707 |
| Document: 0001437749-26-021707-index-headers.html | 0001437749-26-021707 |
| Document: 0001437749-26-021707-index.html | 0001437749-26-021707 |
| Document: 0001437749-26-021707.txt | 0001437749-26-021707 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | DEF 14A | $1.90 | awaiting T+20 | — | $1.93 (+1.58%) |
Sep 22, 2026 4w ago | 8-K | $2.28 $1.96 | ▼ −14.04% | ▼ −14.72% | $1.93 (−15.35%) |
Jun 25, 2026 17w ago | 8-K | $2.17 $2.16 | ▼ −0.46% | ▼ −1.72% | $1.93 (−11.06%) |
Apr 2, 2026 29w ago | 8-K | $2.66 $2.55 | ▲ +4.14% | ▲ +13.12% | $1.93 (+27.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers